1
|
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
|
J Natl Cancer Inst
|
2009
|
3.89
|
2
|
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
|
J Clin Oncol
|
2014
|
3.07
|
3
|
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
|
Gynecol Oncol
|
2007
|
2.20
|
4
|
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
|
Clin Cancer Res
|
2002
|
2.16
|
5
|
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
Clin Cancer Res
|
2011
|
2.09
|
6
|
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
|
J Natl Cancer Inst
|
2004
|
1.63
|
7
|
Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
|
Am J Surg Pathol
|
2009
|
1.62
|
8
|
BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
|
Clin Cancer Res
|
2004
|
1.61
|
9
|
Genome-wide association studies of cancer.
|
J Clin Oncol
|
2010
|
1.45
|
10
|
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
|
Cancer
|
2011
|
1.32
|
11
|
SGO White Paper on ovarian cancer: etiology, screening and surveillance.
|
Gynecol Oncol
|
2010
|
1.27
|
12
|
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
|
Gynecol Oncol
|
2003
|
1.23
|
13
|
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
|
Mod Pathol
|
2011
|
1.15
|
14
|
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
|
Cancer Prev Res (Phila)
|
2011
|
1.10
|
15
|
Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).
|
Int J Gynecol Cancer
|
2013
|
1.04
|
16
|
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
|
Cancer
|
2011
|
1.01
|
17
|
Genome-wide association studies of cancer predisposition.
|
Hematol Oncol Clin North Am
|
2010
|
0.97
|
18
|
Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.96
|
19
|
Hereditary ovarian cancer in Ashkenazi Jews.
|
Fam Cancer
|
2004
|
0.91
|
20
|
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.
|
Clin Cancer Res
|
2002
|
0.90
|
21
|
Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
|
J Clin Oncol
|
2008
|
0.87
|
22
|
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
|
Gynecol Oncol
|
2012
|
0.86
|
23
|
Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
|
Curr Opin Oncol
|
2011
|
0.84
|
24
|
How should women with early-onset endometrial cancer be evaluated for lynch syndrome?
|
J Clin Oncol
|
2007
|
0.82
|
25
|
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
|
Breast Cancer Res Treat
|
2010
|
0.80
|
26
|
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
|
Gynecol Oncol
|
2009
|
0.80
|
27
|
Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.
|
J Clin Oncol
|
2009
|
0.79
|
28
|
The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.
|
Gynecol Oncol
|
2006
|
0.79
|
29
|
Screening for familial ovarian cancer: a ray of hope and a light to steer by.
|
J Clin Oncol
|
2012
|
0.78
|
30
|
Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery.
|
Gynecol Oncol
|
2005
|
0.78
|
31
|
Does a BRCA mutation plus tamoxifen equal hysterectomy?
|
Gynecol Oncol
|
2007
|
0.78
|
32
|
Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
|
Am J Surg Pathol
|
2016
|
0.77
|
33
|
Screening and prevention of hereditary gynecologic cancers.
|
Semin Oncol
|
2007
|
0.77
|
34
|
Modeling genetic risk of breast cancer.
|
JAMA
|
2007
|
0.77
|
35
|
Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
|
Gynecol Oncol
|
2004
|
0.77
|
36
|
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
|
Gynecol Oncol
|
2011
|
0.76
|
37
|
Reducing the risk of gynecologic cancer in the Lynch syndrome.
|
N Engl J Med
|
2006
|
0.76
|
38
|
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
39
|
ATR mutations in endometrial cancer: a window into the role of mismatch repair defects.
|
J Clin Oncol
|
2009
|
0.75
|